Drugs for HER-2-positive Breast Cancer /

Drugs for HER-2-positive Breast Cancer /

Detalles Bibliográficos
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Sibilia, Maria. (Editor ), Zielinski, Christoph C. (Editor ), Bartsch, Rupert. (Editor ), Grunt, Thomas W. (Editor )
Formato: eBook
Lenguaje:English
Publicado: Basel : Springer Basel : Imprint: Springer, 2011.
Edición:1st ed. 2011.
Colección:Milestones in Drug Therapy,
Materias:
Pharmacology.
Oncology  .
Cancer research.
Antibodies.
Immunology.
Internal medicine.
Pharmacology/Toxicology.
Oncology.
Cancer Research.
Internal Medicine.
Tabla de Contenidos:
  • Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt)
  • The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden)
  • Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger)
  • Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello)
  • Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu)
  • Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni)
  • Beyond trastuzumab: Second generation targeted therapies for HER2
  • positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Ejemplares similares